UNSPSC 51422332: Dexamethasone acefurate

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4N6E1T46B, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate 17-(2-furaoate) but more generally known as dexamethasone acefurate, which bears US NIH Compound Identifier 168903. European Medicines Agency schedules Dexamethasone acefurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07018MIG.

UNSPSC 51422332 Dexamethasone acefurate is a Commodity code that shows a significant mismatch between its nominal pharmaceutical scope and recent state and local procurement activity. The single recent opportunity in the dataset—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems, not dexamethasone acefurate. This divergence suggests the code may be incorrectly tagged in state and local procurement systems or that the recent activity does not reflect the code's intended scope of use.

The Seminole County opportunity represents community health and opioid-response procurement, requiring 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB, with a response deadline of July 26, 2026, includes E-Verify compliance, drug-free workplace certification, standard insurance requirements (workers' compensation, commercial general liability, professional liability), and potential FEMA funding with associated federal regulatory compliance obligations. The contract term runs two years with a one-year renewal option on a fixed-fee basis. No other recent state and local opportunities under this code are present in the dataset, limiting visibility into broader purchasing patterns or geographic spread beyond Florida.